#South Korea #Seoul #Latin America #Dx&Vx #KRNA

Dx&Vx's Strategic Agreements in Latin America

In a remarkable move within the biopharmaceutical landscape, Dx&Vx, a South Korean biopharmaceutical company listed under DXVX and KRX: 180400, has significantly advanced its operations in Latin America. Only within a two-month period, specifically in July and August, the company inked two critical material transfer agreements (MTAs) with partners across the region. This swift expansion marks an important step for Dx&Vx, known for its innovative KRNA platform, aimed at stabilizing nucleic acids at room temperature.

A Milestone in Partnership Development

The first of these agreements was established with a prominent Argentine biopharmaceutical firm, a well-respected player in the local vaccine development and manufacturing sector. The collaborative deal came just a month after the initial engagement at the BIO International Convention held in June, where both companies explored potential synergies. This swift negotiation process illustrates a mutual alignment in goals and capabilities, fostering an environment ripe for innovation.

The second agreement followed shortly after, with one of the leading public health institutions in the region. This partnership, however, was the culmination of a rigorous and thorough ten-month technical review, indicating the high standards required by public entities when establishing such critical partnerships. This institution is notable for its involvement in the production of vaccines, including contributions to global COVID-19 vaccination efforts.

Rigorous Validation Meets Market Demand

The nature of these agreements provides a dual validation of the KRNA technology, showcasing its adaptability across both private and public sector needs. The technology’s success in passing the demanding validation processes of both swift-moving private entities and the rigorous evaluations of public health bodies signifies a robust product-market fit. It underscores the growing recognition of the pressing need for nucleic acid storage solutions that can operate effectively in regions like Latin America, where maintaining ultra-cold chain conditions can be a significant challenge due to geographical and infrastructural constraints.

With the announcement of these two agreements, the total number of KRNA MTAs in Latin America has now reached five. The demand for room-temperature nucleic acid stabilization technologies is particularly pronounced in areas characterized by tropical and subtropical climates, emphasizing the applicability and necessity of Dx&Vx's offerings in these markets.

Latin America: A Booming Pharmaceutical Market

Indeed, the Latin American pharmaceutical landscape is on a notable upward trajectory. According to forecasts, this market is predicted to escalate from USD 136 billion in 2025 to USD 250.6 billion by 2034, with an impressive compound annual growth rate (CAGR) of 7.03%. Notably, the biopharmaceutical segment is experiencing even more rapid growth, projected to surge from USD 35.6 billion to USD 81.6 billion during the same period, reflecting a CAGR of 9.67%. Argentina's growth alone is forecasted to elevate from USD 12.3 billion in 2025 to USD 21.8 billion by 2034, representing vast potential for companies like Dx&Vx.

Statements From Leadership

Kwon Kyu-Chan, the CEO of Dx&Vx, expressed excitement about these developments, stating the Argentine agreement, swiftly concluded after just a month of discussions, highlights the excellence of their KRNA technology. He emphasized the importance of the public health institution's agreement, achieved after extensive engagement, as a critical milestone toward solidifying a presence in Latin America’s public procurement market.

About KRNA

The KRNA platform, which was trademarked last year, offers a revolutionary approach to nucleic acid stabilization, applicable across a variety of modalities including mRNA vaccines, RNA therapeutics, DNA vaccines, and much more. This technology signifies a transformative advancement in medical applications, propelling effective healthcare solutions in challenging environments.

As Dx&Vx continues its innovative journey, it is evident that the strategic partnerships formed will not only bolster their position in Latin America but also usher in a new era of accessibility and effectiveness in healthcare solutions for the region.